Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe

European Urology

Volumn 74, Issue 1, 2018, Pages 37-45

  de Bono, Johann S ^a   Chowdhury, Simon ^b,c,d   Feyerabend, Susan ^e   Elliott, Tony ^f   Grande, Enrique ^g   Melhem Bertrandt, Amal ^h   Baron, Benoit ⁱ   Hirmand, Mohammad ^j   Werbrouck, Patrick ^k   Fizazi, Karim ^l  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c KING S COLLEGE HOSPITAL   (United Kingdom)

^d ST THOMAS HOSPITAL   (United Kingdom)

^e Studienpraxis Urologie   (Germany)

^f CHRISTIE HOSPITAL   (United Kingdom)

^g HOSPITAL RAMÓN Y CAJAL   (Spain)

^h ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

ⁱ Astellas Pharma Global Development   (Netherlands)

^j Medivation Inc   (United States)

^k AZ GROENINGE   (Belgium)

^l INSTITUT GUSTAVE ROUSSY   (France)

more..

Author keywords

Abiraterone acetate; Enzalutamide; Metastatic castration resistant prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ENZALUTAMIDE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; PHENYLTHIOHYDANTOIN;

AGED; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRAIN INFARCTION; CASTRATION RESISTANT PROSTATE CANCER; CONSTIPATION; DECREASED APPETITE; DISEASE EXACERBATION; DRUG FATALITY; DRUG SAFETY; FALLING; FATIGUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT HISTORY OF CHEMOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SIDE EFFECT; TREATMENT DURATION; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG RESISTANCE; EUROPE; MIDDLE AGED; PATHOLOGY; PHASE 4 CLINICAL TRIAL; TREATMENT OUTCOME;

ABIRATERONE ACETATE; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EUROPE; HUMANS; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PREDNISONE; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

EID: 85028334438     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2017.07.035     Document Type: Article

References (30)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. http://globocan.iarc.fr.
2. Mottet N, Bellmunt J, Briers E, et al. European Association of Urology. Guidelines on prostate cancer. http://uroweb.org/guideline/prostate-cancer/.
3. Beer, T.M., Armstrong, A.J., Sternberg, C.N., et al. Enzalutamide in men with chemotherapy-naive metastatic prostate cancer (mCRPC): results of phase III PREVAIL study. J Clin Oncol, 32(Suppl 4), 2014 abs LBA1.
4. Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
5. Shore, N.D., Chowdhury, S., Villers, A., et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 17 (2016), 153–163.
6. Tran, C., Ouk, S., Clegg, N.J., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324 (2009), 787–790.
7. Penson, D.F., Armstrong, A.J., Concepcion, R., et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol 34 (2016), 2098–2106.
8. de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
9. Ryan, C.J., Smith, M.R., de Bono, J.S., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368 (2013), 138–148.
10. Fizazi, K., Scher, H.I., Molina, A., et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13 (2012), 983–992.
11. Loriot, Y., Bianchini, D., Ileana, E., et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24 (2013), 1807–1812.
12. Noonan, K.L., North, S., Bitting, R.L., Armstrong, A.J., Ellard, S.L., Chi, K.N., Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24 (2013), 1802–1807.
13. Gillessen, S., Attard, G., Beer, T.M., et al. Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol 73 (2018), 178–211.
14. Azad, A.A., Eigl, B.J., Murray, R.N., Kollmannsberger, C., Chi, K.N., Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 67 (2015), 23–29.
15. Badrising, S.K., van der Noort, V., van den Eertwegh, A.J., et al. Prognostic parameters for response to enzalutamide after docetaxel and abiraterone treatment in metastatic castration-resistant prostate cancer patients; a possible time relation. Prostate 76 (2016), 32–40.
16. Badrising, S., van der Noort, V., van Oort, I.M., et al. Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment. Cancer 120 (2014), 968–975.
17. Bianchini, D., Lorente, D., Rodriguez-Vida, A., et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 50 (2014), 78–84.
18. Brasso, K., Thomsen, F.B., Schrader, A.J., et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. Eur Urol 68 (2015), 317–324.
19. Cheng, H.H., Gulati, R., Azad, A., et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostatic Dis 18 (2015), 122–127.
20. Schrader, A.J., Boegemann, M., Ohlmann, C.H., et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65 (2014), 30–36.
21. Zhang, T., Dhawan, M.S., Healy, P., et al. Exploring the clinical benefit of docetaxel or enzalutamide after disease progression during abiraterone acetate and prednisone treatment in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 13 (2015), 392–399.
22. Thomsen, F.B., Røder, M.A., Rathenborg, P., Brasso, K., Borre, M., Iversen, P., Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate. Scand J Urol 48 (2014), 268–275.
23. Suzman, D.L., Luber, B., Schweizer, M.T., Nadal, R., Antonarakis, E.S., Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone. Prostate 74 (2014), 1278–1285.
24. Miyake, H., Hara, T., Tamura, K., et al. Comparative assessment of efficacies between 2 alternative therapeutic sequences with novel androgen receptor-axis-targeted agents in patients with chemotherapy-naive metastatic castration-resistant prostate cancer. Clin Genitourin Cancer 15 (2017), e591–e597, 10.1016/j.clgc.2016.12.015.
25. Maughan, B.L., Luber, B., Nadal, R., Antonarakis, E.S., Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 77 (2017), 33–40.
26. Petrelli, F., Coinu, A., Borgonovo, K., et al. Enzalutamide after docetaxel and abiraterone acetate treatment in prostate cancer: a pooled analysis of 10 case series. Clin Genitourin Cancer 13 (2014), 193–198.
27. Yamada, Y., Matsubara, N., Tabata, K.I., et al. Abiraterone acetate after progression with enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis. BMC Res Notes, 9, 2016, 471.
28. Li, Z., Bishop, A.C., Alyamani, M., et al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer. Nature 523 (2015), 347–351.
29. Antonarakis, E.S., Lu, C., Wang, H., et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371 (2014), 1028–1038.
30. Del Re, M., Biasco, E., Crucitta, S., et al. The detection of androgen receptor splice variant 7 in plasma-derived exosomal RNA strongly predicts resistance to hormonal therapy in metastatic prostate cancer patients. Eur Urol 71 (2016), 680–687.